The benefit of intravenous immune globulin in the... (2024 study) Skip to main content
Clinical Study Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2024

The benefit of intravenous immune globulin in the treatment of delayed radiation myelopathy.

Naghavi S, Motahharynia A, Fatemi F, Ahmadi E, Mokhtari F, Adibi I, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2024

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

The researchers described one woman with a history of multiple myeloma who developed spinal cord problems after radiation therapy, and they reported how her condition was treated with steroids and then with intravenous immune globulin (IVIG).

What They Found

This single case report describes a 55-year-old woman whose delayed radiation myelitis, which began 11 months after radiation therapy, was treated with methylprednisolone and then IVIG, with her neurological symptoms resolving and a scan lesion enhancement resolving. Methylprednisolone pulse therapy led to complete resolution of her neurological symptoms. At follow-up she had no new neurological complications, but MRI still showed residual enhancement in the thoracic spinal cord. Because of the possibility that the myelitis could progress and the spinal cord could shrink, IVIG was given, and the enhancement then resolved. The authors suggest IVIG could be regarded as a potential therapeutic option when delayed radiation myelopathy is active.

Canadian Relevance

No direct Canadian connection identified.

Study Limitations

This is a report of a single patient with no comparison group, so it cannot show that IVIG caused the MRI improvement, and the lesion may have changed for other reasons, including the earlier steroid treatment.

This plain-language summary was generated with AI assistance from the study's abstract; it has not been individually reviewed by a clinician. Always consult the source study and a qualified healthcare professional. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Clinical Study
Category Radiation Injury
Source Pubmed
PubMed ID 37726423
Year Published 2024
Journal Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
MeSH Terms Humans; Female; Middle Aged; Immunoglobulins, Intravenous; Radiation Injuries; Multiple Myeloma; Magnetic Resonance Imaging; Methylprednisolone; Myelitis, Transverse; Treatment Outcome; Immunologic Factors; Spinal Cord Diseases; Thoracic Vertebrae

Cite This Study

Share

This study relates to Delayed Radiation Injury. Read the full clinical overview, the evidence base, and Canadian treatment access for this condition.

Find a Canadian Clinic Treating Radiation Injury

Browse verified hyperbaric facilities across Canada.

View Canadian Facilities

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last updated: April 1, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology